| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
3'-Amino-3'-deoxyadenosine serves as both a substrate and modulator in studies of nucleic acid synthesis, enzyme specificity, and microbial metabolic pathways. It may target enzymes involved in nucleic acid metabolism. Its antitumor activity suggests inhibition of DNA or RNA synthesis in cancer cells.
|
|---|---|
| ln Vitro |
In vitro, 3'-Amino-3'-deoxyadenosine is an antitumor agent. It is used in biochemical research as a substrate and modulator in studies of nucleic acid synthesis and enzyme specificity. It inhibits cancer cell proliferation. Detailed in vitro data are limited.
|
| ln Vivo |
In vivo studies for 3'-Amino-3'-deoxyadenosine are limited. Its antitumor activity suggests potential for cancer therapy. Animal studies are needed to confirm its in vivo efficacy and safety. As a nucleoside analogue, it may have antiviral or anticancer activity.
|
| Enzyme Assay |
Cell-free assays for 3'-Amino-3'-deoxyadenosine: nucleic acid synthesis inhibition is measured using polymerase assays with radiolabeled nucleotides. The compound is incubated with polymerase enzymes and template DNA/RNA. Incorporation of labeled nucleotides is measured. Enzyme specificity studies use purified enzymes and various substrates.
|
| Cell Assay |
Cellular assays for 3'-Amino-3'-deoxyadenosine: cancer cell lines are cultured and treated with 3'-Amino-3'-deoxyadenosine at concentrations of 0.1-100 µM for 24-72 hours. Cell viability is measured by MTT or CellTiter-Glo assays. DNA and RNA synthesis are measured by [3H]-thymidine or [3H]-uridine incorporation. Apoptosis is assessed by Annexin V/PI staining.
|
| Animal Protocol |
In vivo animal studies for 3'-Amino-3'-deoxyadenosine: xenograft mouse models of cancer would be used. Mice are implanted with cancer cells and treated with 3'-Amino-3'-deoxyadenosine at doses of 1-10 mg/kg. Tumor growth, nucleic acid synthesis inhibition, and toxicity are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 3'-Amino-3'-deoxyadenosine: as a nucleoside analogue (molecular weight 266.26), it may have moderate oral bioavailability. It is likely phosphorylated intracellularly to the active nucleotide form. Metabolism and elimination pathways require further investigation.
|
| Toxicity/Toxicokinetics |
Toxicity of 3'-Amino-3'-deoxyadenosine: comprehensive toxicity data are limited. As a nucleoside analogue, it may have myelosuppressive and immunosuppressive effects at high doses. It is for research use only and not approved for clinical use.
|
| References |
[1]. Gerber, Nancy Nichols, et al. 3'-Amino-3'-deoxyadenosine, an antitumor agent from Helminthosporium.
|
| Additional Infomation |
3'-Amino-3'-deoxyadenosine is a research compound with potential applications in antitumor and nucleic acid research. It is available as a reference standard for pharmacological studies. Its mechanism involves modulation of nucleic acid synthesis. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C10H14N6O3
|
|---|---|
| Molecular Weight |
266.26
|
| Exact Mass |
266.113
|
| CAS # |
2504-55-4
|
| PubChem CID |
65102
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
2.08g/cm3
|
| Boiling Point |
657.6ºC at 760 mmHg
|
| Melting Point |
260-261 °C
|
| Flash Point |
351.5ºC
|
| Vapour Pressure |
3.43E-18mmHg at 25°C
|
| Index of Refraction |
1.935
|
| LogP |
-1.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
334
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C([C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C(N)N=CN=C32)O1)O)N)O
|
| InChi Key |
ILDPUOKUEKVHIL-QYYRPYCUSA-N
|
| InChi Code |
InChI=1S/C10H14N6O3/c11-5-4(1-17)19-10(7(5)18)16-3-15-6-8(12)13-2-14-9(6)16/h2-5,7,10,17-18H,1,11H2,(H2,12,13,14)/t4-,5-,7-,10-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S)-4-amino-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolan-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7557 mL | 18.7786 mL | 37.5573 mL | |
| 5 mM | 0.7511 mL | 3.7557 mL | 7.5115 mL | |
| 10 mM | 0.3756 mL | 1.8779 mL | 3.7557 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
